RVG29 modified liposomes loaded with paclitaxel

The RVG29 modification on the liposomes provides a targeted approach to deliver paclitaxel specifically to neuronal cells, potentially for the treatment of neurological disorders or brain tumors. The RVG29 peptide interacts with nAChR on neuronal cells, promoting the endocytosis of the liposomes and subsequent release of the paclitaxel within the targeted cells.RVG29 modified liposomes loaded with paclitaxel offer the benefit of targeted drug delivery to neuronal cells, improving the efficacy and selectivity of paclitaxel treatment.RVG29 is a peptide derived from the rabies virus glycoprotein, which has a high affinity for the neuronal acetylcholine receptor (nAChR), specifically present on neuronal cells. By modifying liposomes with RVG29, they can be targeted specifically to neuronal cells, allowing for enhanced drug delivery to these cells.

msds of RVG29 modified liposomes loaded with paclitaxel